ASSEMBLY BIOSCIENCES, INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
SIGNA TURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASSEMBLY BIOSCIENCES, INC. | ||
| Date: March 20, 2025 | By: | /s/ Jason A. Okazaki |
|---|---|---|
| Name: | Jason A. Okazaki | |
| Title: | Chief Executive Officer and President |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jason A. Okazaki and John O. Gunderson, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this report, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Jason A. Okazaki | Chief Executive Officer, President and Director | March 20, 2025 |
| Jason A. Okazaki | (Principal Executive Officer and Principal Financial Officer) | |
| /s/ Jeanette M. Bjorkquist | Executive Director, Accounting and Treasury | March 20, 2025 |
| Jeanette M. Bjorkquist | (Principal Accounting Officer) | |
| /s/ William R. Ringo, Jr. | Chairman of the Board | March 20, 2025 |
| William R. Ringo, Jr. | ||
| /s/ Anthony E. Altig | Director | March 20, 2025 |
| Anthony E. Altig | ||
| /s/ Tomas Cihlar, Ph.D. | Director | March 20, 2025 |
| Tomas Cihlar, Ph.D. | ||
| /s/ Gina Consylman | Director | March 20, 2025 |
| Gina Consylman | ||
| /s/ Robert D. Cook II | Director | March 20, 2025 |
| Robert D. Cook II | ||
| /s/ Sir Michael Houghton, Ph.D. | Director | March 20, 2025 |
| Sir Michael Houghton, Ph.D. | ||
| /s/ Lisa R. Johnson-Pratt, M.D. | Director | March 20, 2025 |
| Lisa R. Johnson-Pratt, M.D. | ||
| /s/ Susan Mahony, Ph.D. | Director | March 20, 2025 |
| Susan Mahony, Ph.D. | ||
| /s/ John G. McHutchison, A.O., M.D. | Director | March 20, 2025 |
| John G. McHutchison, A.O., M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.